Press Releases

April 28, 2025

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025

April 28, 2025

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025

View Release

February 27, 2025

Frontier Medicines to Participate in Two Upcoming March Investor Conferences

View Release

January 9, 2025

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

View Release

January 8, 2025

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

View Release

July 23, 2024

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

View Release

June 25, 2024

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

View Release

April 9, 2024

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

View Release

March 21, 2024

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

View Release

February 27, 2024

Frontier Medicines to Participate in Upcoming Investor Conferences

View Release

February 22, 2024

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

View Release

January 3, 2024

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

View Release

May 8, 2023

Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer

View Release

April 16, 2023

Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting

View Release

March 14, 2023

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

View Release

February 28, 2023

Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development

View Release

January 5, 2023

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

View Release

January 5, 2023

Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

View Release

January 4, 2023

Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference

View Release

November 8, 2022

Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors

View Release

November 1, 2022

Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference

View Release

August 25, 2022

Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel

View Release

July 14, 2022

Frontier Medicines Announces Distinguished Oncologist Dr. Pasi Jänne Joins its Scientific Advisory Board

View Release

June 21, 2022

Frontier Medicines Announces Prominent Oncologist Dr. Scott Kopetz Joins its Scientific Advisory Board

View Release

June 2, 2022

Frontier Medicines to Present at the Jefferies Healthcare Conference

View Release

March 9, 2022

Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting

View Release

March 8, 2022

Frontier Medicines Announces the Appointment of Monique Bobadilla as Chief People and Culture Officer

View Release

February 8, 2022

Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board

View Release

January 10, 2022

Frontier Medicines Announces Advancement of First Program Under Global Partnership with AbbVie

View Release

January 5, 2022

Frontier Medicines to Present at the 40th Annual J.P. Morgan Healthcare Conference

View Release

December 9, 2021

Frontier Medicines to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference

View Release

November 17, 2021

Frontier Medicines Announces the Appointment of Marguerite Hutchinson, J.D., as Chief Business Officer

View Release

November 10, 2021

Frontier Medicines to Present at Two Upcoming Investor Conferences in November

View Release

September 23, 2021

Frontier Medicines to Present at the Cantor Global Healthcare Conference

View Release

July 19, 2021

Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

View Release

May 18, 2021

Frontier Medicines to Present at Two Upcoming Investor Conferences

View Release

March 31, 2021

Frontier Medicines Appoints Seasoned Executive Gregory Chow as Chief Financial Officer

View Release

March 30, 2021

Frontier Medicines Appoints Drug Development Expert David M. Goldstein, Ph.D., to its Board of Directors

View Release

January 8, 2021

Frontier Medicines to Present at the 39th Annual J.P. Morgan Healthcare Conference

View Release

December 2, 2020

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

View Release

November 11, 2019

Chemical & Engineering News Names Frontier Medicines One of Its 10 Chemistry Start-Ups to Watch

View Release

September 23, 2019

FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019

View Release

July 31, 2019

Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies

View Release

June 25, 2019

Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease

View Release